Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)

NCT04406389 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

14

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

COVID-19

Interventions

DRUG: Enoxaparin sodium
DRUG: Unfractionated heparin
DRUG: Fondapariniux
DRUG: Argatroban

Sponsor

Weill Medical College of Cornell University